67,153 Shares in Agios Pharmaceuticals, Inc. $AGIO Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. bought a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 67,153 shares of the biopharmaceutical company’s stock, valued at approximately $2,696,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of AGIO. Invesco Ltd. lifted its position in shares of Agios Pharmaceuticals by 28.6% during the first quarter. Invesco Ltd. now owns 107,367 shares of the biopharmaceutical company’s stock worth $3,146,000 after purchasing an additional 23,852 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Agios Pharmaceuticals by 207.6% in the first quarter. Russell Investments Group Ltd. now owns 8,558 shares of the biopharmaceutical company’s stock valued at $251,000 after purchasing an additional 5,776 shares in the last quarter. American Century Companies Inc. increased its stake in Agios Pharmaceuticals by 9.6% during the 1st quarter. American Century Companies Inc. now owns 114,947 shares of the biopharmaceutical company’s stock worth $3,368,000 after buying an additional 10,110 shares during the period. Rafferty Asset Management LLC increased its stake in Agios Pharmaceuticals by 33.2% during the 1st quarter. Rafferty Asset Management LLC now owns 93,627 shares of the biopharmaceutical company’s stock worth $2,743,000 after buying an additional 23,314 shares during the period. Finally, Kodai Capital Management LP acquired a new stake in Agios Pharmaceuticals during the 1st quarter worth approximately $1,485,000.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $24.59 on Wednesday. The stock has a market cap of $1.43 billion, a PE ratio of -3.51 and a beta of 0.87. The stock’s fifty day moving average is $34.53 and its two-hundred day moving average is $36.36. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The business had revenue of $12.88 million during the quarter, compared to analysts’ expectations of $10.49 million. During the same period in the prior year, the firm posted $16.22 EPS. The business’s quarterly revenue was up 43.3% compared to the same quarter last year. On average, research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on AGIO. Citigroup started coverage on shares of Agios Pharmaceuticals in a research note on Wednesday, November 26th. They issued a “buy” rating and a $38.00 price target for the company. Truist Financial set a $32.00 target price on Agios Pharmaceuticals in a report on Monday, November 24th. JPMorgan Chase & Co. lowered their target price on Agios Pharmaceuticals from $37.00 to $20.00 and set a “neutral” rating for the company in a research note on Friday, November 21st. Bank of America cut their price target on Agios Pharmaceuticals from $54.00 to $32.00 and set a “buy” rating on the stock in a report on Thursday, November 20th. Finally, Royal Bank Of Canada lowered Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their price target for the company from $57.00 to $28.00 in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $35.78.

Insider Activity at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 3,651 shares of the business’s stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $36.77, for a total transaction of $134,247.27. Following the completion of the sale, the chief financial officer owned 33,870 shares in the company, valued at approximately $1,245,399.90. The trade was a 9.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sarah Gheuens sold 3,302 shares of the firm’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $43.92, for a total value of $145,023.84. Following the transaction, the insider directly owned 61,727 shares in the company, valued at approximately $2,711,049.84. The trade was a 5.08% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 7,553 shares of company stock valued at $305,001 in the last 90 days. Insiders own 4.93% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.